Compare Match Group Inc (MTCH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Match Group Inc trades at $41.48 (market cap $9.53B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8× Match Group Inc's market cap, and Match Group Inc pays the higher dividend (1.93%). Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MTCH | REGN | |
|---|---|---|
Market Cap | $9.53B | $76.14B |
Volume | 3,228,794 | 500,239 |
Sector | Media | Health |
52-Week High | $44.40 | $852.03 |
52-Week Low | $28.90 | $557.73 |
Typical Hold Time | 115 Days | 107 Days |
Enterprise Value | $12.49B | $70.85B |
Dividend Yield | 1.93% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $40.86, up 0.59% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a P/E of 14.71, net income margin of 20.17%, and consistent cash flow generation. Recent earnings beat expectations in Q2 2026, and positive news highlights product innovation and growth in Hinge.
The outlook is positive, supported by margin expansion and strategic initiatives, but risks include high debt levels and competitive pressures. Wall Street sentiment is bullish with a $42.29 price target, offering modest upside from current levels.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
